Fennec Pharmaceuticals Inc. will release its second quarter 2026 financial results on August 11, 2026, before U.S. markets open. The company, which specializes in treatments to reduce chemotherapy-induced hearing loss, will host a conference call and webcast to discuss its financial and business performance. Investors can access the live webcast via the company’s website, with a replay available for 30 days. This update follows Fennec's ongoing commercialization of PEDMARK®, a drug approved in the U.S. and Europe to protect cancer patients from ototoxicity caused by platinum-based chemotherapy.
Chainlink (LINK) surged 15% over the past week, breaking through the $9.04 resistance to reach $9.56, supported by a 123% spike in trading volume and a 16% rise in derivatives open interest. Large transactions hit a five-month high, with major holder...
Zoom Communications is rated a buy due to its attractive 15.6 price-to-earnings ratio and potential 28.5% stock price increase to $136.20 per share. The company has expanded beyond video meetings by integrating AI and enhancing its enterprise offerin...
On August 17, Ripple minted 10 million RLUSD stablecoins on the XRP Ledger, increasing the circulating supply to approximately 1.711 billion tokens with a market cap near $1.71 billion. This minting confirms token issuance but does not prove immediat...
Bitcoin rose above $64,000 during Asian trading despite a nearly 3% weekly decline, with most major cryptocurrencies also down except Hyperliquid's HYPE token, which gained 9% weekly. The U.S. dollar weakened, influenced by disappointing retail sales...
Solana (SOL) price stabilizes around $75.55, supported by seven weeks of positive ETF inflows totaling $10.26 million last week, signaling sustained institutional interest. The token faces critical resistance between $78 and $80, which it must surpas...
